Status: Recruiting
IASO-782 in Autoimmune Hematological Diseases
This study is a randomized, double-blinded, and placebo-controlled phase Ia clinical study in subjects with autoimmune hematological diseases. The study is designed to assess the safety and tolerability of IASO-782 for the treatment of autoimmune haematological diseases (ITP and wAIHA).
Participants needed: 16
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Shanghai IASO Biotechnology Co., LtdUpdated: May 29, 2026Locations: 2
Eligibility criteria
Age 18-65 years [+7]
History of other primary malignant neoplasm within 5 years of screening [+13]